Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.31 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13816909 | 0.71 | SIGMAR1 (0.36) | SLC6A3ABCC9KCNJ11 | |
| SCHEMBL29844568 | 0.71 | SIGMAR1 (0.36) | SLC6A3ABCC9KCNJ11 | |
| SCHEMBL15156019 | 0.70 | SLC6A3 (0.41) | SLC6A3 | |
| SCHEMBL27663500 | 0.70 | ABCC9 (0.39) | SLC6A3ABCC9KCNJ11 | |
| SCHEMBL17295795 | 0.70 | SLC6A3 (0.41) | SLC6A3 | |
| SCHEMBL30949533 | 0.70 | ABCC9 (0.39) | SLC6A3ABCC9KCNJ11 | |
| SCHEMBL29498995 | 0.67 | PDE4A (0.31) | SLC6A3 | |
| SCHEMBL14845490 | 0.66 | HTR1A (0.41) | SLC6A3 | |
| SCHEMBL20522779 | 0.66 | SLC6A3 (0.42) | SLC6A3 | |
| SCHEMBL18586775 | 0.66 | PDE2A (0.41) | SLC6A3ABCC9KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110038890-A1 | Cellular And Viral Inactivation | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-02-17 | — | — | US | disclosed |
| US-20110038890-A1 | Cellular And Viral Inactivation | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-02-17 | — | — | US | disclosed |
| WO-2009131606-A2 | VIRAL INACTIVATION USING CROSSLINKERS AND DETERGENTS | BELANGER JULIE M (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110038890-A1 | Cellular And Viral Inactivation | PDIA5, HAVCR2, MAVS | SLC6A3 4825/4885ABCC9 4538/4885KCNJ11 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.